Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholde...(rom the National Institute onDrug Abuse ...),Health

Corporate Shared Services (CSS)

CSS costs associated with finance, IT, HR, business development and administration activities totaled $7.8 million for the three months ending September 29, 2007, compared to $8.4 million for the third quarter in 2006. This decrease reflects our ongoing efforts to lower infrastructure costs. Current period expenses include $1.5 million of legal and other professional fees related to the anticipated sale of the Biologics business unit announced on September 11, 2007, while the prior period expenses included expense related to the review of certain stock compensation awards.

Recent Accomplishments

-- NicVAX Phase 2b 12-month data presented at the American Heart

Association Scientific Sessions on November 7, 2007 continue the

positive trends and findings previously reported, demonstrating NicVAX

efficacy in supporting statistically significant and continuous

abstinence rates by dose as well as by antibody response. These

positive results are the subject of a recent press release, issued Nov.

7, 2007. They support continued development of this product candidate

and underpin on-going partnership discussions.

-- Shareholder approval for the sale of the Nabi Biologics strategic

business unit to Biotest AG, a significant step toward the successful

completion of our strategic alternatives process.

Upcoming Milestones

Nabi is currently working to achieve the following corporate milestones in 2007:

-- Successfully close the sale of Nabi Biologics and Corporate Shared

Services to Biotest Pharmaceuticals

-- Continue to advance development partnerships for NicVAX and the Gram-

positive programs

Third Quarter Financial Results Conference Call

The company will
'/>"/>